Research programme

Learning more about the prevalence, incidence, duration and the risk factors associated with carriage of serogroup A meningococcal bacteria in African countries will support vaccination programmes with the new serogroup A meningococcal vaccine, MenAfriVac™.

MenAfriVac™ is being produced by the Serum Institute of India Ltd and has undergone clinical trials in Africa where encouraging preliminary immunogenicity results were obtained.  This vaccine is now being rolled out in countries of the African meningitis belt.

Read how the research methods of the MenAfriCar project will investigate the above factors and find out more about the African countries involved.

Mix preparation and electrophoresis for PCR at CERMES Niamey. © CERMES